Evercore ISI analyst Ross Muken initiated Twist Bioscience with an Outperform rating and $30.50 price target, telling investors that disruptive potential of synthetic biology is "massive" across industries. Twist's core business of DNA synthesis and its NGS Tools business give it "two shots on goal" to maintain greater than 25% growth over the next 3-5 years. Investors in the stock also get "two call options," namely the company's potential to provide synthetic RNA and DNA to RNAi therapeutic companies to help develop APIs and its potential to use DNA as a storage medium.